80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]黃陽,陳靜波,林貴山.動態(tài)監(jiān)測循環(huán)腫瘤細(xì)胞對寡轉(zhuǎn)移非小細(xì)胞肺癌聯(lián)合治療預(yù)后的價值[J].福建醫(yī)藥雜志,2023,45(05):8-12.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(05):8-12.
點擊復(fù)制

動態(tài)監(jiān)測循環(huán)腫瘤細(xì)胞對寡轉(zhuǎn)移非小細(xì)胞肺癌聯(lián)合治療預(yù)后的價值()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
45
期數(shù):
2023年05期
頁碼:
8-12
欄目:
臨床研究
出版日期:
2023-10-15

文章信息/Info

Title:
Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer
文章編號:
1002-2600(2023)05-0008-05
作者:
黃陽; 陳靜波; 林貴山1
福建省立醫(yī)院腫瘤內(nèi)科(福州 350001)
Author(s):
HUANG Yang;  CHEN Jingbo;  LIN Guishan
Department of Medical oncology, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, China
關(guān)鍵詞:
非小細(xì)胞肺癌;  寡轉(zhuǎn)移;  循環(huán)腫瘤細(xì)胞;  預(yù)后
Keywords:
non-small cell lung cancer;  oligometastases;  circulating tumor cells;  prognosis
分類號:
R734.2
文獻(xiàn)標(biāo)志碼:
B
摘要:
目的 探討動態(tài)監(jiān)測循環(huán)腫瘤細(xì)胞(CTC)在預(yù)測寡轉(zhuǎn)移非小細(xì)胞肺癌(NSCLC)患者全身治療及局部放射治療預(yù)后的潛在應(yīng)用價值。方法 2019年1月至2020年12月確診為無EGFR、ALK和ROS1突變的寡轉(zhuǎn)移NSCLC患者52例,經(jīng)全身治療后,40例影像學(xué)評估為部分緩解或疾病穩(wěn)定的患者納入研究。所有患者接受帕博利珠單抗維持治療,其中20例(50.0%)還接受所有轉(zhuǎn)移病灶的放射治療。收集所有患者維持治療前、治療后12個月的CTC及其生存資料。據(jù)患者維持治療前至治療后12個月CTC值的變化,將40例患者分為CTC下降組、穩(wěn)定組和上升組,進(jìn)行生存分析。結(jié)果 Kaplan-Meier生存分析顯示,CTC不同變化組中位無進(jìn)展生存期(PFS)分別為30.86、23.80、17.49個月(χ2=8.616,P=0.013)。CTC不同變化組中位總生存期分別為32.23、26.64、19.66個月(χ2=10.809, P=0.004)。在單因素及多因素Cox回歸中,對轉(zhuǎn)移灶進(jìn)行放療(HR=1.863,95%CI:1.263,2.749,P=0.002)、不同CTC變化(HR=2.562,95%CI:1.452,4.522,P=0.001)為PFS的獨立預(yù)后因素。結(jié)論 動態(tài)監(jiān)測CTC可以預(yù)測無EGFR、ALK、ROS1突變的寡轉(zhuǎn)移NSCLC患者聯(lián)合治療的預(yù)后,具有一定的臨床應(yīng)用價值。
Abstract:
Objective To investigate the potential application value of dynamic monitoring of circulating tumor cell(CTC)in predicting the prognosis of systemic treatment and local radiotherapy in patients with oligometastatic non-small cell lung cancer(NSCLC).Methods From January 2019 to December 2020, 52 patients diagnosed with oligometastatic NSCLC without EGFR, ALK, and ROS1 mutations were included in the study.After systemic treatment, 40 patients with partial response or stable disease evaluated by imaging examination were included in the study.All patients received Pembrolizumab maintenance treatment, of which 20 patients(50.0%)also received radiotherapy for all metastasis.Collect CTC values of all patients before and 12 months after maintenance treatment and survival data.According to the changes in CTC values between before and 12 months after maintenance treatment, 40 patients were divided into a decreasing group(with a decrease in CTC count), a stable group(with no change in CTC count), and an increasing group(with an increase in CTC count)for survival analysis.Results Kaplan-Meier survival analysis showed that the median progress free survival(PFS)of different CTC change groups was 30.86, 23.80, and 17.49 months(χ2=8.616, P=0.013).The median overall survival(OS)of different groups of CTC change groups were 32.23, 26.64, and 19.66 months(χ2=10.809, P=0.004).The result of univariate and multivariate Cox regression revealed that radiotherapy for all metastatic lesions(HR=1.863,95%CI: 1.263,2.749, P=0.002)and different CTC changes(HR=2.562,95%CI: 1.452,4.522, P=0.001)were independent prognostic factors for PFS.Conclusion Dynamic monitoring of CTC can predict the prognosis of oligometastatic NSCLC patients without EGFR, ALK, or ROS1 mutations in combination therapy, and has certain clinical value.

參考文獻(xiàn)/References:

[1] Hellman S,Weichselbaum R R.Oligometastases[J].J Clin Oncol, 1995, 13: 8-10.
[2] Mok T S K, Wu Y L, Kudaba I, et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet,2019,393(10183):1819-1830.
[3] Petrelli F, Ghidini A, Cabiddu M, et al.Addition of radiotherapy to the primary tumour in oligometastatic NSCLC: A systematic review and meta-analysis[J]. Lung Cancer, 2018,126:194-200.
[4] Chiou V L, Burotto M.Pseudoprogression and immune-related response in solid tumors[J]. J Clin Oncol,2015,33(31):3541-3543.
[5] Champiat S, Dercle L, Ammari S, et al.Hyperprogressive disease is a new pattern of progression in cancer patients treated by Anti-PD-1/PD-L1[J]. Clin Cancer Res,2017,23(8):1920-1928.
[6] Zhang J, Chen K, Fan Z H.Circulating Tumor Cell Isolation and Analysis[J]. Adv Clin Chem,2016,75(4):1-31.
[7] Krebs M G, Sloane R, Priest L, et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer[J]. J Clin Oncol,2011,29(12):1556-1563.
[8] Muinelo-Romay L, Vieito M, Abalo A, et al.Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-Line systemic treatment[J]. Cancers(Basel),2014,6(1):153-165.
[9] Juan O, Vidal J, Gisbert R, et al.Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine[J]. Clin Transl Oncol, 2014,16(7):637-643.
[10] Hirose T, Murata Y, Oki Y, et al.Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer[J]. Oncol Res, 2012,20(2-3):131-137.
[11] Wang J, Wang K, Xu J, et al.Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis[J]. PLoS One,2014,9(1):e78070.
[12] Dorsey J F, Kao G D, MacArthur K M, et al.Tracking viable circulating tumor cells(CTCs)in the peripheral blood of non-small cell lung cancer(NSCLC)patients undergoing definitive radiation therapy: pilot study results[J]. Cancer, 2015,121(1):139-149.
[13] Jianpeng L.Significance of circulating tumor cells in non-small-cell lung cancer patients: prognosis, chemotherapy efficacy, and survival[J]. J Healthc Eng,2021,11(9):2680526.
[14] Chen X, Wang X, He H, et al.Combination of circulating tumor cells with serum carcinoembryonic antigen enhances clinical prediction of non-small cell lung cancer[J]. PLoS One, 2015,10(5):e0126276.

相似文獻(xiàn)/References:

[1]林清華　吳聯(lián)平　劉加夫　陳友軒　 齊春能　林玉瓊　黃小紅　鄭　靜.晚期非小細(xì)胞肺癌患者胸水液基細(xì)胞學(xué)蠟塊中新抗體D5F3檢測的臨床價值[J].福建醫(yī)藥雜志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(05):3.
[2]陳新富 劉 寧 劉加夫.CK19在非小細(xì)胞肺癌淋巴結(jié)微轉(zhuǎn)移中的檢測價值(附90例分析)[J].福建醫(yī)藥雜志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(05):6.
[3]林 瀟 陳愉生 李鴻茹.查爾森合并癥指數(shù)及簡化合并癥評分對晚期非小細(xì)胞肺癌預(yù)后的影響[J].福建醫(yī)藥雜志,2020,42(05):23.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):23.
[4]李榮賓,黃延延,林賢賓,等.IGF1/RPI3K/Akt通路及其調(diào)控對非小細(xì)胞肺癌血管生成擬態(tài)形成影響的研究[J].福建醫(yī)藥雜志,2023,45(03):112.
[5]鐘穎,鄒立,陳聲池.EGFR T790M突變豐度對阿美替尼治療晚期非小細(xì)胞肺癌療效的影響[J].福建醫(yī)藥雜志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(05):17.[doi:10.20148/j.fmj.2024.01.005]

備注/Memo

備注/Memo:
基金項目:福建省科技廳重點項目(2019Y0055)
1 通信作者,Email:[email protected]
更新日期/Last Update: 2023-10-15